Bioterrorism-Related Anthrax in Index Medicus/Medline, Current Contents, Excerpta Medica, and Other Databases

Total Page:16

File Type:pdf, Size:1020Kb

Bioterrorism-Related Anthrax in Index Medicus/Medline, Current Contents, Excerpta Medica, and Other Databases A Peer-Reviewed Journal Tracking and Analyzing Disease Trends Vol.8, No.10, October 2002 Bioterrorism-related anthrax In Index Medicus/Medline, Current Contents, Excerpta Medica, and other databases Editorial Board Editors Electronic Access Dennis Alexander, Addlestone Surrey, United Kingdom Joseph E. McDade, Founding Editor Retrieve the journal electronically on the Ban Allos, Nashville, Tennesee, USA Atlanta, Georgia, USA World Wide Web (WWW) at http:// Michael Apicella, Iowa City, Iowa, USA www.cdc.gov/eid or from the CDC home page Abdu F. Azad, Baltimore, Maryland, USA D. Peter Drotman, Interim Editor-in-Chief Ben Beard, Atlanta, Georgia, USA Atlanta, Georgia, USA (http://www.cdc.gov). Barry J. Beaty, Ft. Collins, Colorado, USA Stephen S. Morse, Perspectives Editor Announcements of new table of contents can Martin J. Blaser, New York, New York, USA New York, New York, USA be automatically e-mailed to you. To subscribe, S.P. Borriello, London, United Kingdom send an e-mail to [email protected] with the fol- Donald S. Burke, Baltimore, Maryland, USA Brian W.J. Mahy, Perspectives Editor lowing in the body of your message: subscribe Charles Calisher, Ft. Collins, Colorado, USA Atlanta, Georgia, USA Arturo Casadevall, Bronx, New York, USA EID-TOC. Thomas Cleary, Houston, Texas, USA Phillip J. Baker, Synopses Editor Anne DeGroot, Providence, Rhode Island, USA Bethesda, Maryland, USA Vincent Deubel, Lyon, France Stephen Ostroff, Dispatches Editor J. Stephen Dumler, Baltimore, Maryland, USA Atlanta, Georgia, USA Durland Fish, New Haven, Connecticut, USA Richard L. Guerrant, Charlottesville, Virginia, USA Patricia M. Quinlisk, Letters Editor Emerging Infectious Diseases Scott Halstead, Arlington, Virginia, USA Des Moines, Iowa, USA Seyed Hasnain, Hyderabad, India Emerging Infectious Diseases is published David L. Heymann, Geneva, Switzerland Polyxeni Potter, Managing Editor monthly by the National Center for Sakae Inouye, Tokyo, Japan Atlanta, Georgia, USA Infectious Diseases, Centers for Disease Peter B. Jahrling, Frederick, Maryland, USA Control and Prevention (CDC), 1600 Clifton Mohamed A. Karmali, Guelph, Ontario, Canada International Editors Charles King, Cleveland, Ohio, USA Road, Mailstop D61, Atlanta, GA 30333, USA. Keith Klugman, Atlanta, Georgia, USA Patrice Courvalin Telephone 404-371-5329, fax 404-371-5449, Bruce R. Levin, Atlanta, Georgia, USA Paris, France e-mail [email protected]. Myron Levine, Baltimore, Maryland, USA Stuart Levy, Boston, Massachusetts, USA Takeshi Kurata All material published in Emerging Infectious Thomas J. Marrie, Edmonton, Alberta, Canada Tokyo, Japan Diseases is in the public domain and may be John E. McGowan, Jr., Atlanta, Georgia, USA S.K. Lam used and reprinted without special permission; Patrick S. Moore, New York, New York, USA Kuala Lumpur, Malaysia proper citation, however, is appreciated. Philip P. Mortimer, London, United Kingdom Fred A. Murphy, Davis, California, USA John S. Mackenzie Use of trade names is for identification only Barbara E. Murray, Houston, Texas, USA Brisbane, Australia and does not imply endorsement by the Public P. Keith Murray, Ames, Iowa, USA Health Service or by the U.S. Department of James M. Musser, Hamilton, Missouri, USA Hooman Momen Rosanna W. Peeling, Geneva, Switzerland Rio de Janeiro, Brazil Health and Human Services. David H. Persing, Seattle, Washington, USA Sergey V. Netesov Gianfranco Pezzino, Topeka, Kansas, USA j Novosibirsk Region, Russian Federation Emerging Infectious Diseases is printed on acid- Richard Platt, Boston, Massachusetts, USA free paper that meets the requirements of ANSI/ Didier Raoult, Marseille, France Diana Walford NISO 239.48-1992 (Permanence of Paper) Leslie Real, Atlanta, Georgia, USA London, United Kingdom David Relman, Palo Alto, California, USA Pierre Rollin, Atlanta, Georgia, USA Nancy Rosenstein, Atlanta, Georgia, USA Production Editors Connie Schmaljohn, Frederick, Maryland, USA Kevin Burlison Ira Schwartz, Valhalla, New York, USA Robert Shope, Galveston, Texas, USA Mary Anne Castranio Bonnie Smoak, Bethesda, Maryland, USA Teresa M. Hood Rosemary Soave, New York, New York, USA Anne D. Mather The opinions expressed by authors contribut- P. Frederick Sparling, Chapel Hill, North Carolina, USA Ava W. Navin ing to this journal do not necessarily reflect the Jan Svoboda, Prague, Czech Republic opinions of the Centers for Disease Control Robert Swanepoel, Sandringham, South Africa Carol D. Snarey and Prevention or the institutions with which Phillip Tarr, Seattle, Washington, USA Reginald S. Tucker Timothy Tucker, Cape Town, South Africa the authors are affiliated. Elaine Tuomanen, Memphis, Tennessee, USA Cathy E. Young David Walker, Galveston, Texas, USA Mary E. Wilson, Cambridge, Massachusetts, USA Full text free online at www.cdc.gov/eid The print journal is available at no charge to public health professionals YES, I would like to receive Emerging Infectious Diseases. Please print your name and business address in the box and return by fax to 404-371-5449 or mail to EID Editor CDC/NCID/MS D61 1600 Clifton Road, NE Atlanta, GA 30333 Moving? Please give us your new address (in the box) and print the number of your old mailing label here______________ On the Cover: Norman Bacillus anthracis Aerosolization Rockwell (1894–1978). Post- man Reading Mail (Saturday Associated with a Contaminated Evening Post cover, 18 Febru- Mail Sorting Machine .........................................................1044 ary 1922). P.M. Dull et al. Courtesy of the Curtis Publish- ing Company, Indianapolis, Epidemiologic Investigations of Indiana, USA. Bioterrorism-Related Anthrax, New Jersey, 2001 ..............1048 C.M. Greene et al. About the Cover see pg 1184 Bioterrorism-Related Anthrax: International Response by the Centers for Disease Control and Prevention ......................................................1056 C.S. Polyak et al. Two-Component Direct Fluorescent-Antibody Assay for Rapid Bioterrorism-Related Anthrax Identification of Bacillus anthracis......................................1060 Anthrax Bioterrorism: Lessons B.K. De et al. Learned and Future Directions.......................................... 1013 J.M. Hughes and J.L. Gerberding Inhalational Anthrax Outbreak among Postal Workers, Washington, D.C., 2001...............1066 Public Health in the Time of Bioterrorism .......................... 1015 P.K. Dewan et al. B.A. Perkins et al. Surveillance for Anthrax Cases Investigation of Bioterrorism-Related Anthrax, Associated with Contaminated Letters, United States, 2001: Epidemiologic Findings .................... 1019 New Jersey, Delaware, and Pennsylvania, 2001...............1073 D.B. Jernigan et al. C.G. Tan et al. First Case of Bioterrorism-Related Bioterrorism-Related Anthrax Inhalational Anthrax in the United States, Surveillance, Connecticut, September– Palm Beach County, Florida, 2001.................................... 1029 December, 2001.................................................................1078 M.S. Traeger et al. A.A. Williams et al. First Case of Bioterrorism-Related Environmental Sampling for Inhalational Anthrax, Florida, 2001: Spores of Bacillus anthracis...............................................1083 North Carolina Investigation .............................................. 1035 E.H. Teshale et al. J.-M. Maillard et al. Call-Tracking Data and the Public Opening a Bacillus anthracis–Containing Health Response to Bioterrorism-Related Anthrax ............1088 Envelope, Capitol Hill, Washington, D.C.: J.A. Mott et al. The Public Health Response............................................. 1039 V.P. Hsu et al. Coordinated Response to Reports of Possible Anthrax Contamination, Idaho, 2001...................1093 L. Tengelsen et al. Laboratory Response to Anthrax The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the Bioterrorism, New York City, 2001 .....................................1096 institutions with which the authors are affiliated. M.B. Heller et al. Specific, Sensitive, and Quantitative Collaboration between Public Health and Enzyme-Linked Immunosorbent Assay for Law Enforcement: The Constitutional Challenge ...............1157 Human Immunoglobulin G Antibodies to E.P. Richards Anthrax Toxin Protective Antigen ....................................... 1103 C.P. Quinn et al. Anthrax Perspectives Molecular Subtyping of Bacillus anthracis Epidemic Anthrax in the Eighteenth and the 2001 Bioterrorism-Associated Century, the Americas ........................................................1160 Anthrax Outbreak, United States.........................................1111 D.M. Morens A.R. Hoffmaster et al. Epidemiologic Response to Anthrax Outbreaks: Sequencing of 16S rRNA Gene: A Field Investigations, 1950–2001.........................................1163 Rapid Tool for Identification of Bacillus anthracis............... 1117 M.E. Bales et al. C.T. Sacchi et al. Antimicrobial Postexposure Prophylaxis Another Dimension for Anthrax: Adverse Events and Adherence ..................... 1124 Night of Two Town Meetings ..............................................1175 C.W. Shepard et al. M.L. Cartter Anthrax Postexposure Prophylaxis in Postal Workers, Connecticut, 2001.................................... 1133 Letters J.L. Williams et al. Evaluation and Validation of a Real- Adherence to Antimicrobial Inhalational Time Polymerase Chain Reaction Assay Anthrax Prophylaxis among Postal Workers, for
Recommended publications
  • Peter Freeman
    First Assistant Director Peter Freeman 30 Birch Grove Windsor, Berks SL4 5RT Tel : +44 (0)1753 862226 Mobile: +44 (0)7774 700 747 SA Mobile: +27 (0)76 4377 963 e-mail: [email protected] Languages: Greek, Basic French Over 12 years experience with Movie Magic Scheduling. South African ResidenceVisa. Advanced Production Safety Certificate, BBC Total Concept Safety Certificate Recent credits include: FEATURES “Gulliver’s Travels” Jack Black as Gulliver in modern retelling of classic tale. (Additional Assistant Director) Cast Inc: Jack Black, Jason Segel, Billy Connolly, Emily Blunt. Directors: Chris O’Dell (2nd Unit), UPM/1st AD: Terry Bamber (2nd Unit), “Broken Thread” Modern day ghost story. Shot in India, Isle of Man and London. Cast inc: Linus Roache, Saffron Burrows Director: Mahesh Matai Producer: Deepak Nayar A.P: Paul Sarony “These Foolish Things” Romantic comedy set in 1920’s theatre-land. Shot in and around Cheltenham. Cast inc: Angelica Huston, Lauren Bacall, Terence Stamp, Andrew Lincon. Director: Julia Taylor-Stanley Producers: Julia Taylor-Stanley, Paul Sarony “Spirit Trap” Horror/ghost story. Shot in Romania and the UK for Archangel Productions. Cast inc: Luke Mably, Sam Troughton, Emma Catherwood and Billy Piper. Director: David Smith Producer: Susie Brooks-Smith A.P: David Higginson / Cathy Lord “Chasing Liberty” Second unit Czech Republic. Cast inc: Mandy Moore, Mark Harmon Director: Andy Cadiff (main unit) Line Prod: Cathy Lord A.P: Hilary Benson “Jane Eyre” Retelling of classic tragic love story. Derbyshire & London Cast inc: William Hurt, Charlotte Gainsburg, Elle Macpherson Director: Franco Zeffirelli Producer: Dyson Lovell A.P: Ray Freeborn Page 2 “Soft Sand, Blue Sea” Film Four.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Determination of Iodate in Iodised Salt by Redox Titration
    College of Science Determination of Iodate in Iodised Salt by Redox Titration Safety • 0.6 M potassium iodide solution (10 g solid KI made up to 100 mL with distilled water) • 0.5% starch indicator solution Lab coats, safety glasses and enclosed footwear must (see below for preparation) be worn at all times in the laboratory. • 250 mL volumetric flask Introduction • 50 mL pipette (or 20 and 10 mL pipettes) • 250 mL conical flasks New Zealand soil is low in iodine and hence New Zealand food is low in iodine. Until iodised salt was • 10 mL measuring cylinder commonly used (starting in 1924), a large proportion • burette and stand of school children were reported as being affected • distilled water by iodine deficiency – as high as 60% in Canterbury schools, and averaging 20 − 40% overall. In the worst cases this deficiency can lead to disorders such as Method goitre, and impaired physical and mental development. 1. Preparation of 0.002 mol L−1 sodium thiosulfate In earlier times salt was “iodised” by the addition of solution: Accurately weigh about 2.5 g of solid potassium iodide; however, nowadays iodine is more sodium thiosulfate (NaS2O3•5H2O) and dissolve in commonly added in the form of potassium iodate 100 mL of distilled water in a volumetric flask. (This gives a 0.1 mol L−1 solution). Then use a pipette to (KIO3). The Australia New Zealand Food Standards Code specifies that iodised salt must contain: “equivalent to transfer 10 mL of this solution to a 500 mL volumetric no less than 25 mg/kg of iodine; and no more than 65 flask and dilute by adding distilled water up to the mg/kg of iodine”.
    [Show full text]
  • Read Ebook {PDF EPUB} Fire in His Eyes by Stella Price Fire in His Eyes by Stella Price
    Read Ebook {PDF EPUB} Fire in His Eyes by Stella Price Fire in His Eyes by Stella Price. Authors Stella and Audra Price (S.A. Price) is doing a HUGE sale for Labor day! Starting Sept 1st and ending Sept 5th the following books will be FREE: FIRE IN HIS EYES SOMETHING DARKER GIVING UP THE GHOST KNOSSOS WEST CONSORT THE SOFT EDGE OF MIDNIGHT. And just to be awesome. you can get the other books in the corresponding series' for 99 cents each Sept. 1-8th! That's series for under 10$! Great deal right? Why not take a chance and get addicted? Here's the links for each series! YOU BURN ME:https://www.amazon.com/Burn-Eververse-Stella-Audra-Price/dp/1484111796/ GIVING UP THE GHOST *FREE*: https://www.amazon.com/Giving-Up-Ghost-Shades-Red/dp/1484104161 THE SERENDIPITY OF KARMA: https://www.amazon.com/Serendipity-Karma-METALCORE-ROMANCE-Shades-ebook/dp/B00CSDEYGS THIS IS FOREVER: https://www.amazon.com/This-Forever-METALCORE-ROMANCE-Shades-ebook/dp/B00GW3XEMK THE BRIDE WORE LATEX: https://www.amazon.com/Bride-Wore-Latex-METALCORE-ROMANCE-ebook/dp/B00HNFGHFM MAKE DAMN SURE:https://www.amazon.com/Make-Damn-Sure-METALCORE-ROMANCE-ebook/dp/B00K5BDLWS THE SELF IMPORTANCE OF LESSER BEINGS: https://www.amazon.com/Self-Importance-Lesser-Beings-METALCORE-ebook/dp/B00K52S74E PIN YOUR WINGS: https://www.amazon.com/Pin-Your-Wings-METALCORE-ROMANCE-ebook/dp/B00QFFEVFO KEEP HER IN PIECES: https://www.amazon.com/Keep-Her-Pieces-METALCORE-ROMANCE-ebook/dp/B00UZUANKW. SOMETHING DARKER*FREE*: https://www.amazon.com/Something-Darker-Inferi-Dii-Book-ebook/dp/B00AOT77GW SOMETHING SINFUL: https://www.amazon.com/Something-Sinful-Inferi-Dii-Book-ebook/dp/B010GMZTIO.
    [Show full text]
  • WHO Model List of Essential Medicines
    WHO Model List of Essential Medicines 15th list, March 2007 Status of this document This is a reprint of the text on the WHO Medicines web site http://www.who.int/medicines/publications/essentialmedicines/en/index.html 15th edition Essential Medicines WHO Model List (revised March 2007) Explanatory Notes The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost‐effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost‐effective treatment. The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost‐effectiveness in a variety of settings. The square box symbol () is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources. Therapeutic equivalence is only indicated on the basis of reviews of efficacy and safety and when consistent with WHO clinical guidelines.
    [Show full text]
  • United States Patent Office Patented Apr
    3,505,222 United States Patent Office Patented Apr. 7, 1970 1. 2 3,505,222 product of a mercaptain with sulfur trioxide. Their metal LUBRICANT COMPOSITIONS salts are represented by the formula: Leonard M. Niebylski, Birmingham, Mich, assignor to O Ethyl Corporation, New York, N.Y., a corporation of Virginia (R-S-S-0--M No Drawing. Filed Mar. 29, 1967, Ser. No. 626,701 5 s (I) Int. C. C10m 5/14, 3/18, 7/36 wherein R is a hydrocarbon radical containing from 1 U.S. C. 252-17 2 Claims to about 30 carbon atoms, M is a metal, and n is the valence of metal M. For example, when M is the monova 0. lent sodium ion, n is 1. ABSTRACT OF THE DISCLOSURE The radical R can be an alkyl, cycloalkyl, aralkyl, The extreme pressure wear properties of base lubri alkaryl, or aryl radical. The radicals may contain other cants including water, hydrocarbons, polyesters, silicones, nonhydrocarbon substituents such as chloro, bromo, iodo, polyethers and halocarbons is enhanced by the addition fluoro, nitro, hydroxyl, nitrile, isocyanate, carboxyl, car of a synergistic mixture of a thiosulfate compound and 15 bonyl, and the like. a lead compound. The useful metals are all those capable of forming Bunte salts. Preferred metals are those previously listed as suitable for forming metal thiosulfates. Of these, the Background more preferred metals are sodium and lead, and lead is 20 the most preferred metal in the Bunte salts. This invention relates to improved lubricant composi Examples of useful Bunte salts include: tions.
    [Show full text]
  • Sodium Nitrite and Sodium Thiosulfate
    PATIENT & CAREGIVER EDUCATION Sodium Nitrite and Sodium Thiosulfate This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Nithiodote Warning This drug may cause low blood pressure and a red blood cell problem called methemoglobinemia. These may be life-threatening. This drug is only for use when cyanide poisoning is life-threatening. This drug must be used with care if it is not known if cyanide poisoning has happened. Talk with the doctor. Tell the doctor if your child has inhaled a lot of smoke or if your child has any of these health problems: Anemia, heart problems, lack of a certain enzyme called congenital methemoglobin reductase deficiency, or lung problems. What is this drug used for? It is used to treat cyanide poisoning. What do I need to tell the doctor BEFORE my child takes this drug? If your child is allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell the doctor about the allergy and what signs your child had. Sodium Nitrite and Sodium Thiosulfate 1/6 If your child is breast-feeding a baby: Be sure your child does not breast-feed a baby while taking this drug. This drug may interact with other drugs or health problems. Tell the doctor and pharmacist about all of your child’s drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe to give this drug with all of your child’s other drugs and health problems.
    [Show full text]
  • Assessing the in Situ Efficacy of Tea Tree Oil As a Topical Antiseptic
    Novasel Australia Pty Ltd Assessing the in situ efficacy of tea tree oil as a topical antiseptic A report for the Rural Industries Research and Development Corporation by S. Messager, K.A. Hammer & T.V. Riley August 2005 RIRDC Publication No 05/113 RIRDC Project No UWA-72A © 2005 Rural Industries Research and Development Corporation. All rights reserved. ISBN 1 74151 176 3 ISSN 1440-6845 Assessing the in situ efficacy of tea tree oil as a topical antiseptic Publication No. 05/113 Project No. UWA-72A The information contained in this publication is intended for general use to assist public knowledge and discussion and to help improve the development of sustainable industries. The information should not be relied upon for the purpose of a particular matter. Specialist and/or appropriate legal advice should be obtained before any action or decision is taken on the basis of any material in this document. The Commonwealth of Australia, Rural Industries Research and Development Corporation, the authors or contributors do not assume liability of any kind whatsoever resulting from any person's use or reliance upon the content of this document. This publication is copyright. However, RIRDC encourages wide dissemination of its research, providing the Corporation is clearly acknowledged. For any other enquiries concerning reproduction, contact the Publications Manager on phone 02 6272 3186. Researcher Contact Details Prof. T. V. Riley University of Western Australia School of Biomedical and Chemical Sciences Microbiology (M502) 35 Stirling Hwy CRAWLEY WA 6009 Phone: (08) 9346 3690 Fax: (08) 9346 2912 Email: [email protected] In submitting this report, the researcher has agreed to RIRDC publishing this material in its edited form.
    [Show full text]
  • Chemical %Concentration CAS
    Sebozole Shampoo Page 1of 5 Sebozole Shampoo SAFETY DATA SHEET (1) IDENTIFICATION Name: Sebozole Shampoo Use: veterinary skin care Supplier: Vetoquinol USA (Tomlyn Products) 4250 N. Sylvania Ave Fort Worth, TX 76137 Tel: ( 817)529-7500 Fax: (817)529-7506 (2) HAZARD(S) IDENTIFICATION Hazard Classification: Non Hazardous as defined by 29CFR Part 1910.1200 (3) COMPOSITION/INFORMATION ON INGREDIENTS Common Name: Sebozole Shampoo Composition: A blend of proprietary ingredients which make a veterinary dermatologic care product. Chemical %Concentration CAS Sodium Thiosulfate 3.13 10102-17-7 Miconazole Nitrate 2.0 22916-47-8 Salicylic Acid 2.0 69-72-7 Chloroxylenol 1.0 88-04-0 Sodium Olefin Sulfonate 25 6843-57-6 PEG 150 Pentaerythrityl Tetratstearate 5 130249-48-8 Lauramide DEA 5 92680-75-6 Propylene Glycol 5 57-55-6 Ultrez 21 1 9003-39-8 Sodium Hydroxide 1 1310-73-2 Fragrance 0.5 Kathon CG 0.1 6118-96-6 FD&C yellow #5 0.0013 84842-94-4 FD&C Blue #1 0.0013 3844-45-9 Purified Water 49 7732-18-5 Sebozole Shampoo Page 2 of 5 (4) First Aid Measures Ingestion • In case of ingestion call a physician and poison control. EYE • If product enters eye, rinse thouroughly with cool fresh water for 10 to 15 minutes. If irritation persists, seek medical attention. • a burning sensation, excessive tears, sensitivity to light, swelling and redness of the conjunctiva and increasedblinking. • Limited evidence or practical experience suggests, that the material may cause eye irritation in a substantial number of individuals.Prolonged eye contact may cause inflammation characterized by a redness of the conjunctiva (similar to windburn SKIN • none INHALED • None (5) FIRE-FIGHTING MEASURES Suitable Extinguisher: FOAM, DRY POWDER, WATER, CO2 Special Precautions: None Special Protective Equipment: None (6) ACCIDENTAL RELEASE PROCEDURES Personal Precautions: None.
    [Show full text]
  • Stanford Storage Groups
    STANFORD STORAGE Ethylene Glycol G Sigmacote L GROUPS Ficoll G Silver Nitrate E Formaldehyde w/ methanol L Sodium Acetate G CHEMICAL GRP Formaldehyde <37%, G Sodium Azide X 1-Butanol or 2- L 20% NBF Formalin Sodium Bicarbonate G 1-Propanol L Formamide L Sodium Bisulfite G 2-Mercaptoethanol L Formic Acid D Sodium Borate (borax) G Acetic Acid, Glacial D Glutaraldehyde D Sodium Carbonate G Acetic Anhydride L Glycerol L Sodium Chloride G Acetone L Glycine G Sodium Citrate, Dihydrate G Acrolein L Guanidine Hydrochloride G Sodium Hydroxide C Acrylamide G Guanidine Thiocyanate C Sodium Hypochlorite E Agarose G Gluconic Acid G (Bleach) Ammonium Acetate G HEPES D Sodium Per(anything) E Ammonium Chloride G Hydrochloric Acid F Sodium Phosphate G Ammonium Hydroxide C Hydrogen Peroxide, 30% E Sodium Sulfide, Anhydrous X Ammonium Molybdate G Imidazole A Sodium Thiosulfate G Ammonium Nitrate E Iodine E Succinic Acid G Ammonium Persulfate E Isoamyl or isobutyl alcohol L Sucrose G Ammonium Sulfate G Isopropanol L Sulfuric Acid F Ammonium Sulfide L Magnesium Chloride G Tannic Acid D Ascorbic Acid G Magnesium Sulfate G TEMED A BIS & BIS-Acrylamide G Maleic Acid D TES free acid G BIS TRIS A Mercaptoethanol L Tetracycline G Boric Acid G MES G Trichloroacetic Acid D Calcium Chloride G Methanol L Tricine G Cesium Chloride G N-Methyl-2-Pyrrolidone A Toluene L Cesium Fluoride F Mineral Oil L Triethanolamine A Cesium Hydroxide C Nitric Acid E TRIS, base A CHAPS G Oxalic Acid D TRIS Hydrochloride G Chloroform G Paraformaldehyde A Triton X-100 G Chromerge E Perchloric
    [Show full text]
  • 2003 Programme Review
    About 4 Review of 2003 Statement of Promises In 2003, Channel 4 took the diverse experience of living in Britain now head on. Across its current affairs, drama and satirical entertainment, it mirrored the passions of a society again waking up to political choice. In the range of its contemporary documentary, Without Channel 4’s investment, it is from the enjoyable to the searing, it displayed doubtful whether there would be a significant the uninhibited openness of the personal; in its independent production sector in the UK, and it education programmes it tested the ambiguous would certainly be far less diverse. connections between our present sensibility and the past that shapes and challenges it. Competitive Performance It also placed Britain in perspective in the This has been a challenging year for Channel way it continuously explored and sought to 4 as for other terrestrial channels. Our ratings understand the rest of the world. performance has been resilient in peak time (forecast 9.4% in 2003 versus 9.7% in 2002) Too much public service television retails a but we have lost share in daytime and later soft focus, “heritage” view of Britain, protecting at night. the old and comforting from the modern and dangerous. At its best Channel 4 refused such a Landmarks of 2003 false distinction. The Deal Second Generation Where Channel 4 invented, others followed. Operatunity Programmes pioneered on Channel 4 were The Death of Klinghoffer openly copied by the BBC, ITV and Five. The Hajj – Greatest Trip on Earth Channel 4 now, as much as it ever did, does the Channel 4 News in Iraq original thinking for the rest of British television.
    [Show full text]
  • THE BIRTHDAY PARTY by Harold Pinter
    PRESS RELEASE Mark Goucher and Everyman Theatre Cheltenham present THE BIRTHDAY PARTY By Harold Pinter Tuesday 7 January 2020 • NATIONAL TOUR OF THE BIRTHDAY PARTY STARRING MICHELLE COLLINS, TRISTAN GEMMILL AND PAUL HICKEY TO OPEN AT EVERYMAN THEATRE, CHELTENHAM ON 2 APRIL 2020 • THE TOUR WILL VISIT SALFORD, OXFORD, GUILDFORD, EDINBURGH, NORWICH, CARDIFF, RICHMOND AND MILTON KEYNES • HEAD SHOTS AVAILABLE TO DOWNLOAD HERE Michelle Collins will play Meg Boles, Tristan Gemmill will play Goldberg and Paul Hickey will play McCann in a national UK tour of Harold Pinter's comedy of menace which will receive a dramatic new re-imagining from the team behind Waiting for Godot. Opening at Everyman Theatre, Cheltenham and following a two-year celebration of the works of Harold Pinter in the West End, this is Pinter’s most popular and widely performed play. Further casting to be announced in due course. The tour will open at Everyman Theatre in Cheltenham from 2 – 11 April (with press night on 7 April) followed by The Lowry Quays (14-18 April), Oxford Playhouse 21- 25 April), Guildford Yvonne Arnaud (28 April – 2 May), Edinburgh Kings (5-9 May), Norwich Theatre Royal (12- 16 May), Cardiff New (26–30 May), Richmond Theatre (2-6 June) and Milton Keynes Theatre (9- 13 June). Set in a dilapidated seaside boarding house the mysterious Stanley Webber receives a visit from two sinister strangers, Goldberg and McCann. They arrive on Stanley's birthday - or is it? What do they want and why do they want to turn Stanley's quite world upside down? The Everyman Theatre's Creative Director, Paul Milton, brings together this fine cast to present Pinter's classic darkly comic masterpiece with design by Dawn Allsopp, Lighting design by Michael Hall and Sound design by Steve Anderson.
    [Show full text]